SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-265717
Filing Date
2023-10-30
Accepted
2023-10-30 08:35:52
Documents
16
Period of Report
2023-10-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d567471d8k.htm   iXBRL 8-K 50904
2 EX-10.1 d567471dex101.htm EX-10.1 271726
3 EX-10.2 d567471dex102.htm EX-10.2 131660
4 EX-99.1 d567471dex991.htm EX-99.1 24129
8 GRAPHIC g567471g1029211639755.jpg GRAPHIC 2365
  Complete submission text file 0001193125-23-265717.txt   719703

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20231029.xsd EX-101.SCH 2890
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20231029_lab.xml EX-101.LAB 17995
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20231029_pre.xml EX-101.PRE 11288
10 EXTRACTED XBRL INSTANCE DOCUMENT d567471d8k_htm.xml XML 3396
Mailing Address 221 CRESCENT STREET BLDG. 17, SUITE 401 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BLDG. 17, SUITE 401 WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

IRS No.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 231357526
SIC: 8071 Services-Medical Laboratories